查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008494

胃麻痺治療市場：2026-2032年全球市場預測（按產品類型、藥物類別、給藥途徑、最終用戶和分銷管道分類）

Gastroparesis Drugs Market by Product Type, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，胃麻痺治療市場價值將達到 48.7 億美元，到 2026 年將成長至 52.4 億美元，到 2032 年將達到 79.7 億美元，複合年成長率為 7.27%。

主要市場統計數據
基準年 2025 48.7億美元
預計年份：2026年 52.4億美元
預測年份 2032 79.7億美元
複合年成長率 (%) 7.27%

全面而權威地概述了胃麻痺症的臨床複雜性、治療限制和商業性考量，這些因素共同塑造了胃麻痺症的治療模式。

胃麻痺的治療具有持續的臨床複雜性、未被滿足的需求以及傳統藥物療法與新興藥物療法並存的特點。患者會出現多種症狀，現有治療方案難以有效管理，而臨床醫師必須在長期治療過程中權衡療效、安全性和耐受性。在此背景下，產業相關人員面臨監管、成本壓力以及證明病患報告結果（PRO）顯著改善的挑戰。

簡要概述了重塑胃麻痺症治療方法和商業化策略的突破性科學、監管和商業性變革。

近年來，由於藥物研發的進步、監管機構對以患者為中心的終點指標的重視以及替代給藥技術的成熟，胃麻痺領域發生了變革性的變化。製藥創新者越來越重視針對特定路徑以改善胃動力並減少全身副作用的分子。同時，口服生物製藥製劑技術的成熟和經皮給藥概念的出現，拓展了臨床醫生可用的藥理學工具，使其能夠提供超越單純療效聲明的差異化價值提案。

分析性評論：2025 年美國關稅上調將如何加劇胃麻痺藥物整個供應鏈網路中的供應鏈、採購和定價趨勢。

美國提高關稅為全球藥品供應鏈和籌資策略帶來了新的複雜性，尤其是那些依賴進口活性成分（API）和最終製劑的藥品。先前透過跨國採購API來最佳化成本的生產網路，必須重新評估供應商合格、緩衝庫存政策以及近岸外包的可行性，以緩解關稅造成的成本波動。同時，各公司正在審查與合約研發生產機構（CDMO）的合約條款，以分擔或承擔增加的成本負擔，這反過來又影響了與經銷商和下游支付方的價格談判。

從多方面細分的觀點揭示了產品類型、治療領域、給藥途徑、分銷管道和最終用戶如何獨特地影響臨床引入和商業策略。

細分市場分析揭示了產品類型、藥物類別、給藥途徑、分銷管道和最終用戶等方面的不同動態，這些因素共同影響著治療方法的採納和商業性執行。根據產品類型，市場可分為品牌藥和學名藥。品牌藥通常基於目標臨床數據和延長生命週期策略，而學名藥優先考慮成本效益和提高處方箋採納率。這些相互矛盾的趨勢為生產者帶來了不同的獎勵。品牌藥開發商優先考慮差異化和證據深度，而學名藥生產商則專注於最佳化生產規模和分銷管道。

一項策略性區域分析，旨在揭示美洲、歐洲、中東和非洲以及亞太地區的差異如何影響胃麻痺治療的取得、監管和商業化。

區域趨勢對整個胃麻痺治療領域的進入途徑、監管預期和商業模式都具有顯著影響。在美洲，獎勵激勵機制、嚴格的支付方審查以及多樣化的報銷環境並存，這促使企業需要製定差異化的打入市場策略和價值論證。此外，美洲各地臨床實踐的差異會影響處方集選擇以及新藥和成熟藥物的相對採用率，而供應鏈的韌性仍然是營運中的重中之重。

這份公司簡介深入分析了創新、合作和營運韌性如何重新定義胃麻痺治療研發公司的競爭策略。

胃麻痺領域的企業層面措施體現了創新、生命週期管理和營運效率之間的平衡。原廠藥公司持續投資於標靶機制，以期提高療效和耐受性，並經常將臨床開發與生物標記策略和患者報告結局指標相結合，以展現差異化價值。同時，專科藥和學名藥生產商則利用成本和供應優勢，搶佔現有產品仍被臨床接受的細分市場。

為行業領導者提供切實可行的、高優先級的建議，以加強證據生成、供應韌性和基於價值的胃麻痺治療應用。

在胃麻痺症治療領域尋求競爭優勢的領導者應優先考慮以患者為中心的療效指標和基於實證醫學的框架，以證明其在真實臨床實踐中的療效。早期投資於病患報告結局指標、長期安全性登記和可操作的試驗設計，能夠增強對支付方和醫療服務提供者的價值提案，並有助於將該療法與現有治療方法分開來。與臨床醫生和患者權益倡導網路進行策略合作，可以加速有意義終點的選擇和應用，同時加強上市後數據的收集。

一份透明且嚴謹的調查方法總結，解釋了我們如何透過對主要調查和有針對性的主要訪談進行三角驗證，為利害關係人產生檢驗的見解。

本分析的調查方法結合了系統性的二手資料研究和有針對性的原始資料收集，以確保證據的廣度和深度。二級資訊來源包括同行評審的臨床文獻、監管指導文件和公開的企業披露信息，這些資料被整合起來，用於梳理治療機制、安全性概況和監管先例。為了補充這一基礎，研究人員還對臨床專家、供應鏈高管和醫保報銷系統專家進行了訪談，以即時了解觀點對准入障礙、處方行為和採購趨勢的看法。

明確且具有策略意義的結論，整合了臨床潛力、商業性需求和營運彈性，這對於成功實施胃麻痺治療方案至關重要。

簡而言之，胃麻痺的治療格局正處於一個轉折點，科學進步、政策轉變和實際情況在此交匯，重新定義價值創造。標靶藥理學和給藥技術的進步為改善患者預後帶來了巨大潛力，但這些技術能否在臨床實踐中得到應用，取決於是否有令人信服的證據、與支付方的合作以及能夠滿足門診和居家照護需求的實用給藥模式。同時，關稅和供應鏈脆弱性等宏觀層面的壓力凸顯了韌性和策略採購在維持患者用藥可及性和商業性永續性的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：胃麻痺治療市場：依產品類型分類

  • 品牌商品
  • 學名藥

第9章：胃麻痺治療藥物市場：依藥物類別分類

  • 多巴胺拮抗劑
    • 西沙必利
    • 多姆哌立登
    • 甲氧氯普胺
  • 胃動素受體促效劑
    • 阿奇黴素
    • 紅黴素
  • 血清素受體促效劑
    • Granisetron
    • Ondansetron

第10章：胃麻痺治療藥物市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 經皮吸收

第11章：胃麻痺治療藥物市場：依最終用戶分類

  • 診所
  • 居家照護設施
  • 醫院

第12章：胃麻痺治療藥物市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：胃麻痺治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：胃麻痺治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：胃麻痺治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國胃麻痺治療藥物市場

第17章：中國胃麻痺治療藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Amneal Pharmaceuticals, Inc.
  • ANI Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Atlantic Healthcare PLC
  • Bausch Health Companies Inc.
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Limited
  • Cairn Diagnostics
  • Evoke Pharma, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin International plc
  • Lupin Limited
  • Medtronic PLC
  • Neurogastrx, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Processa Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Theravance Biopharma
  • Vanda Pharmaceuticals Inc.
  • Viatris Inc.
Product Code: MRR-C002B1C996F5

The Gastroparesis Drugs Market was valued at USD 4.87 billion in 2025 and is projected to grow to USD 5.24 billion in 2026, with a CAGR of 7.27%, reaching USD 7.97 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.87 billion
Estimated Year [2026] USD 5.24 billion
Forecast Year [2032] USD 7.97 billion
CAGR (%) 7.27%

A precise and authoritative introduction framing clinical complexity, treatment limitations, and commercial considerations shaping the gastroparesis therapeutic landscape

The therapeutic arena for gastroparesis is characterized by persistent clinical complexity, unmet patient needs, and a mix of legacy and evolving pharmacologic approaches. Patients experience a broad spectrum of symptoms that can be difficult to manage with existing options, while clinicians balance efficacy, safety, and tolerability in long-term care pathways. Against this backdrop, industry players are navigating regulatory scrutiny, cost pressures, and the imperative to demonstrate meaningful improvements in patient-reported outcomes.

This report provides a concise orientation to the clinical and commercial context shaping gastroparesis drugs. It examines drug class dynamics, delivery modalities, distribution pathways, and end-user considerations that influence adoption in inpatient, clinic, and home care settings. By integrating recent clinical evidence with supply chain and policy developments, the introduction sets the stage for deeper analyses that follow, enabling leaders to contextualize tactical choices within a broader therapeutic and operational framework.

A concise synthesis of the transformative scientific, regulatory, and commercial shifts reshaping gastroparesis therapeutics and commercialization strategies

Recent years have seen transformative shifts in the gastroparesis landscape driven by advances in drug development, regulatory focus on patient-centered endpoints, and the maturation of alternative delivery technologies. Pharmaceutical innovators are increasingly prioritizing molecules that target specific mechanistic pathways to improve gastric motility while mitigating systemic adverse effects. Concurrently, the maturation of oral-biologic formulation techniques and transdermal delivery concepts has broadened the pharmacologic toolkit available to clinicians, enabling differentiated value propositions beyond simple efficacy claims.

Commercially, the industry is experiencing strategic convergence between specialty developers, contract manufacturers, and generic producers. This has accelerated lifecycle management strategies for established agents through reformulation and new routes of administration that extend clinical utility. At the same time, payers and providers are shifting toward value-based contracting and outcome-aligned reimbursement, raising the bar for evidence generation and long-term safety monitoring. These combined forces are reshaping market entry strategies, clinical trial design, and commercialization pathways, and they will continue to influence investment priorities and partnership models across the sector.

An analytical review of how elevated U.S. tariffs in 2025 have amplified supply chain, procurement, and pricing dynamics across gastroparesis drug supply networks

The imposition of elevated tariffs in the United States has introduced a conditional layer of complexity into global pharmaceutical supply chains and procurement strategies, particularly for agents reliant on imported active pharmaceutical ingredients and finished dosage forms. Manufacturing networks that previously optimized cost through cross-border API sourcing must now re-evaluate supplier qualification, buffer inventory policies, and nearshoring feasibility to mitigate tariff-driven cost volatility. In parallel, firms are recalibrating contractual terms with contract development and manufacturing organizations to share or absorb incremental cost burdens, which in turn affects pricing negotiations with distributors and downstream payers.

Operationally, increased import levies have prompted a reassessment of inventory strategies for hospital pharmacies, specialty distributors, and retail channels, with many organizations extending lead times and diversifying supplier bases to protect continuity of supply. Clinicians and procurement officers may experience short-term pricing pressure that influences prescribing patterns, particularly where multiple therapeutic alternatives exist. Furthermore, tariff-driven cost increases can constrain manufacturers' flexibility to finance late-stage clinical programs or reformulation initiatives, as capital is reallocated toward ensuring uninterrupted production and compliance. Ultimately, the cumulative impact emphasizes resilience-building measures-regional manufacturing investments, strategic API stockpiles, and tightened quality oversight-to maintain product availability and preserve patient access in an increasingly protectionist trade environment.

A multi-dimensional segmentation lens revealing how product types, therapeutic classes, delivery routes, channels, and end users uniquely influence clinical adoption and commercial strategy

Segmentation analysis reveals differentiated dynamics across product type, drug class, route of administration, distribution channel, and end user that collectively shape therapeutic adoption and commercial execution. Based on Product Type, the landscape distinguishes branded therapies from generics, with branded agents typically anchored by targeted clinical data and lifecycle-extension strategies while generics emphasize cost-efficiency and formulary penetration. These opposing dynamics create distinct incentives for manufacturers: branded developers prioritize differentiation and evidence depth, whereas generic producers focus on manufacturing scale and channel optimization.

Based on Drug Class, the market is studied across Dopamine Antagonists, Motilin Receptor Agonists, and Serotonin Receptor Agonists. The Dopamine Antagonists is further studied across Cisapride, Domperidone, and Metoclopramide, where safety profiles and regulatory legacies govern prescribing limitations and monitoring requirements. The Motilin Receptor Agonists is further studied across Azithromycin and Erythromycin, which offer prokinetic properties but raise concerns about antimicrobial stewardship and long-term tolerability. The Serotonin Receptor Agonists is further studied across Granisetron and Ondansetron, which are primarily utilized for symptom control in specific care settings and may be repurposed or reformulated to enhance delivery. Differentiation across these classes is shaped not only by mechanism of action but also by demonstrable effects on patient-relevant endpoints, regulatory labeling, and long-term safety evidence.

Based on Route Of Administration, the market is studied across Injectable, Oral, and Transdermal approaches, each presenting distinct development and commercialization considerations. Injectable options can offer rapid onset and consistent pharmacokinetics but require clinical settings for administration and introduce cold-chain and device complexities. Oral formulations remain the most practicable for chronic outpatient management, yet they face bioavailability and tolerability constraints that drive reformulation efforts. Transdermal delivery presents an avenue for steady-state exposure and improved adherence but requires investment in device compatibility and robust skin tolerability data.

Based on Distribution Channel, the market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, and channel selection influences reimbursement complexity, patient access pathways, and the economics of specialty versus commodity products. Hospital pharmacies often manage inpatient and acute therapeutic needs and may drive early adoption of novel therapies supported by hospital formularies and therapeutic committees. Online pharmacies have emerged as critical access points for chronic management, where convenience and continuity of supply are weighed against regulatory controls and quality assurance. Retail pharmacies remain central to community-based dispensing and play a pivotal role in patient counseling and adherence support.

Based on End User, the market is studied across Clinics, Home Care Settings, and Hospitals, each shaping the clinical use case and service model for gastroparesis therapies. Clinics frequently manage ambulatory patients requiring ongoing symptomatic management and titration, whereas home care settings demand simplified administration, adherence-support solutions, and remote monitoring capabilities. Hospitals manage acute presentations and complex comorbidities and often influence adoption through institutional protocols and multidisciplinary care pathways. Understanding these segmentation layers helps stakeholders align clinical evidence, pricing strategies, and distribution mechanisms to the distinct needs of each subgroup, thereby informing targeted development and commercialization plans.

A strategic regional analysis illuminating how Americas, Europe, Middle East & Africa, and Asia-Pacific differences impact access, regulation, and commercialization of gastroparesis treatments

Regional dynamics exert a pronounced influence on access pathways, regulatory expectations, and commercial models across the gastroparesis space. In the Americas, incentives for innovation coexist with intense payer scrutiny and diverse reimbursement landscapes that drive differentiated go-to-market tactics and value demonstration requirements. Clinical practice variation across the Americas also shapes formulary selection and the relative uptake of novel versus established agents, while supply chain resilience remains a central operational priority.

In Europe, Middle East & Africa, fragmented regulatory frameworks and heterogeneous payer systems necessitate adaptive market entry strategies that account for localized pricing negotiations, health technology assessment processes, and varying levels of specialist availability. Countries within this expansive region may prioritize different evidence standards or access pathways, creating opportunities for targeted demonstration projects and early-access agreements. In Asia-Pacific, dynamic growth in healthcare infrastructure, expanding specialty care capacity, and rising patient awareness combine to present both opportunity and complexity. Policymakers and providers in Asia-Pacific are increasingly receptive to models that enhance outpatient management and remote-care delivery, which supports the adoption of oral and transdermal innovations. Across all regions, strategic emphasis on supply chain redundancy, regulatory alignment, and evidence generation tailored to local decision-making frameworks is essential for sustained success.

An incisive corporate overview describing how innovation, alliances, and operational resilience are redefining competitive strategies among gastroparesis drug developers

Company-level behavior in the gastroparesis domain reflects a balance between innovation, lifecycle management, and operational efficiency. Innovator firms continue to invest in targeted mechanisms that promise improved efficacy or tolerability, often coupling clinical development with biomarker strategies and patient-reported outcome measures to substantiate differentiated value. At the same time, specialty and generics manufacturers deploy cost and supply advantages to capture clinical segments where established products remain clinically acceptable.

Strategic alliances-spanning licensing, codevelopment, and contract manufacturing-have become common as firms seek to accelerate time-to-market while controlling development cost and complexity. Firms with integrated manufacturing footprints or strong partnerships with contract organizations are better positioned to absorb trade-related disruptions or to pursue regional production. Additionally, companies are increasingly investing in digital therapeutics adjuncts, remote monitoring, and adherence platforms that complement pharmacologic therapy and provide richer real-world evidence. Collectively, these company-level strategies indicate a pragmatic shift toward collaborative, patient-focused, and operationally resilient business models that sustain long-term competitive advantage.

Practical and prioritized recommendations for industry leaders to strengthen evidence generation, supply resilience, and value-based adoption for gastroparesis therapies

Leaders seeking to secure advantage in gastroparesis therapeutics should prioritize evidence frameworks that demonstrate patient-centered outcomes and real-world effectiveness. Early investment in patient-reported outcome measures, long-term safety registries, and pragmatic trial designs will strengthen value propositions for payers and providers and support differentiated positioning versus incumbent therapies. Strategic collaboration with clinicians and patient advocacy networks can accelerate meaningful endpoint selection and uptake while enriching post-launch data capture.

Operationally, companies should diversify supply chains and evaluate selective nearshoring or regional manufacturing options to mitigate tariff sensitivity and procurement disruption. Investing in digital adherence tools and companion care models will increase the stickiness of therapies delivered in home care and outpatient settings, and these adjuncts can be leveraged to generate ongoing real-world evidence. Finally, pricing strategies must be aligned with demonstrated clinical value, with alternative contracting models considered where outcomes can be reliably measured and validated. Taken together, these measures enable firms to balance access, affordability, and innovation in a rapidly evolving therapeutic and policy landscape.

A transparent and rigorous methodological summary describing how secondary research and targeted primary interviews were triangulated to produce validated insights for stakeholders

The research methodology underpinning this analysis combined systematic secondary research with targeted primary data collection to ensure both breadth and depth of evidence. Secondary sources included peer-reviewed clinical literature, regulatory guidance documents, and publicly available corporate disclosures, which were synthesized to map therapeutic mechanisms, safety profiles, and regulatory precedents. This foundation was augmented by primary interviews with clinical specialists, supply chain executives, and reimbursement experts to capture real-time perspectives on access barriers, prescribing behavior, and procurement dynamics.

Data synthesis followed a triangulation process to reconcile divergent perspectives and to validate trends across independent sources. Qualitative insights were coded thematically to identify recurring strategic imperatives and operational constraints, while cross-regional comparisons highlighted contextual differences relevant to market entry and commercialization. Limitations include variability in regional data transparency and the evolving nature of trade policy and clinical evidence, which were explicitly accounted for through sensitivity checks and stakeholder validation sessions. The methodology thus balances rigor and pragmatism, delivering actionable intelligence grounded in multi-stakeholder evidence.

A clear and strategic conclusion that synthesizes clinical promise, commercial imperatives, and operational resilience required for successful gastroparesis program execution

In sum, the gastroparesis therapeutic environment is at an inflection point where scientific progress, policy shifts, and operational realities converge to redefine value creation. Advances in targeted pharmacology and delivery technologies offer genuine promise for improved patient outcomes, yet clinical adoption will depend on compelling evidence, payer alignment, and practical administration models that meet the needs of ambulatory and home care settings. Simultaneously, macro-level pressures such as tariffs and supply chain fragility underscore the importance of resilience and strategic sourcing in maintaining patient access and commercial viability.

The path forward requires integrated strategies that couple robust evidence generation with pragmatic operational planning. Firms that align clinical differentiation with resilient manufacturing, flexible distribution models, and outcome-focused contracting will be best positioned to create sustainable impact for patients and stakeholders alike. The insights compiled here provide a strategic foundation for leaders to refine development priorities, optimize commercial paths, and mitigate policy and supply risks as they pursue durable therapeutic and business outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastroparesis Drugs Market, by Product Type

  • 8.1. Branded
  • 8.2. Generics

9. Gastroparesis Drugs Market, by Drug Class

  • 9.1. Dopamine Antagonists
    • 9.1.1. Cisapride
    • 9.1.2. Domperidone
    • 9.1.3. Metoclopramide
  • 9.2. Motilin Receptor Agonists
    • 9.2.1. Azithromycin
    • 9.2.2. Erythromycin
  • 9.3. Serotonin Receptor Agonists
    • 9.3.1. Granisetron
    • 9.3.2. Ondansetron

10. Gastroparesis Drugs Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Transdermal

11. Gastroparesis Drugs Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care Settings
  • 11.3. Hospitals

12. Gastroparesis Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Gastroparesis Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Gastroparesis Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Gastroparesis Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Gastroparesis Drugs Market

17. China Gastroparesis Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc.
  • 18.7. Amneal Pharmaceuticals, Inc.
  • 18.8. ANI Pharmaceuticals, Inc.
  • 18.9. AstraZeneca PLC
  • 18.10. Atlantic Healthcare PLC
  • 18.11. Bausch Health Companies Inc.
  • 18.12. Bristol-Myers Squibb Company
  • 18.13. Cadila Pharmaceuticals Limited
  • 18.14. Cairn Diagnostics
  • 18.15. Evoke Pharma, Inc.
  • 18.16. GlaxoSmithKline PLC
  • 18.17. Johnson & Johnson Services, Inc.
  • 18.18. Kyowa Kirin International plc
  • 18.19. Lupin Limited
  • 18.20. Medtronic PLC
  • 18.21. Neurogastrx, Inc.
  • 18.22. Novartis AG
  • 18.23. Pfizer, Inc.
  • 18.24. Processa Pharmaceuticals, Inc.
  • 18.25. Sanofi S.A.
  • 18.26. Takeda Pharmaceutical Company Limited
  • 18.27. Theravance Biopharma
  • 18.28. Vanda Pharmaceuticals Inc.
  • 18.29. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GCC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 160. GCC GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 162. GCC GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. G7 GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 188. G7 GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 189. G7 GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. G7 GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. G7 GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. NATO GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 198. NATO GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. NATO GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)